Skip to main content
Premium Trial:

Request an Annual Quote

Applied Markets Watch: Seegene Licenses PCR Tech to BioMerieux for Food Safety

Premium

Seegene said this week that BioMérieux has licensed its DPO and TOCE technologies to develop multiplexed molecular tests for food safety.

Seegene's DPO (dual-priming oligonucleotide) and TOCE (tagging oligonucleotide capture and extension) technologies enable highly multiplexed assays based on real-time PCR.

DPO can be used to block extension of non-specifically primed templates, generating consistently high specificity; while TOCE enables simultaneous multiplexed assays by separating genes that have been amplified by real-time PCR technology based on differences in their melting temperatures, Seegene said.

"We believe that the adoption of our leading multiplexing technology will curtail future food contamination outbreaks, save lives, and help to grow this important market," Seegene CEO and CTO Jong-Yoon Chun said in a statement.

Financial terms of the agreement were not disclosed.

Seegene last year inked a similar licensing agreement for food safety testing with DuPont Nutrition & Health.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.